TAVR Market Heats Up As Medtronic’s CoreValve Wins Early FDA Approval
Executive Summary
Medtronic Inc.’s CoreValve transcatheter aortic valve replacement (TAVR) device won FDA approval in January, months earlier than anticipated, setting the stage for a competitive battle in the US between Medtronic and market leader Edwards Lifesciences Corp. According to Jeffrey Popma, MD, the early approval can be attributed not only to the excellent design and execution of the CoreValve pivotal trial, but also to the new, more collaborative environment that is emerging at the US Food and Drug Administration.
You may also be interested in...
Edwards Wins Latest Round In TAVI Patent Dispute With Medtronic
A jury in Delaware awarded Edwards $393.6 million in damages plus royalties after determining Medtronic’s CoreValve infringes Edwards’ Cribier patent. While Medtronic might be paying royalties to Edwards for the next several years, Medtronic also got some very positive news last week: FDA approved CoreValve for patients too sick for surgery months earlier than expected.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.